Curious about Catalent net worth and financial performance in 2024? With Ando Money, I’ll walk you through Catalent’s revenue drivers, acquisitions, and strategic growth that define its current value.
We’ll explore key financial metrics to give you an in-depth understanding of the company’s financial health.
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | Catalent, Inc. |
| Full Name | Catalent Pharma Solutions |
| Industry | Pharmaceuticals |
| Traded As | NYSE: CTLT |
| ISIN | N/A |
| Founded | 2007 |
| Founders | The Blackstone Group Affiliates |
| Country/Territory | United States |
| Headquarters | Somerset, New Jersey |
| Chief Executive Officer | Alessandro Maselli |
| Number of Employees | 16,900 |
| Market Cap | $10.92 billion |
| Total Assets | $9.75 billion |
| Total Equity | $3.60 billion |
| Revenue | $4.38 billion |
| Net Income | -$1.04 billion |
What is the Net Worth/Market Cap of Catalent in 2024?
As of 2024, Catalent has a market cap of $10.92 billion. This valuation ranks it among the significant players in the pharmaceutical sector.
Compared to other companies in the industry, Catalent maintains a competitive stance.
It is essential to consider its growth strategy, recent acquisitions, and expanding product offerings. If you’re interested in learning about the wealthiest corporations in the sector, check out this page.
Companies related to Catalent:
- Pfizer
- Johnson & Johnson
- AstraZeneca
- Moderna
- Blackstone Group
- Novo Holdings
- Cook Pharmica
- Paragon Bioservices
- Sarepta Therapeutics
- Relthy Laboratories
Catalent Financial Performance Overview
Key Financial Drivers Behind Company Growth
The major financial drivers behind Catalent‘s growth include its strategic expansions, acquisitions, and growing demand for pharmaceutical services.
Catalent’s expertise in drug formulation and manufacturing has allowed it to capture a broad market share in the pharmaceutical sector.
The ability to partner with leading drugmakers like Pfizer and Moderna has also enhanced its brand value and revenue growth, particularly during the pandemic when vaccine production was in high demand.
Revenue Breakdown by Business Segments
Catalent’s revenue in FY 2024 amounted to $4.38 billion. The company primarily operates in two segments: Biologics and Pharma & Consumer Health.
The Biologics segment accounted for approximately 46% of the revenue, driven by a strong demand for manufacturing services in biologic drugs and gene therapies.
Meanwhile, the Pharma & Consumer Health segment contributed 54% of total revenue, benefiting from the increased need for drug delivery technologies.
Pharmaceutical Services as a Revenue Contributor
Catalent provides critical services such as drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing.
These services significantly contribute to Catalent’s revenue, making it a reliable partner in the pharmaceutical industry.
The company’s ability to deliver comprehensive solutions, from drug development to manufacturing, has been instrumental in establishing it as a market leader.
Impact of Recent Acquisitions on Revenue Growth
Catalent’s revenue growth has been accelerated by strategic acquisitions. The acquisition of Paragon Bioservices for $1.2 billion allowed Catalent to enhance its capabilities in gene therapy manufacturing.
Another impactful acquisition was Cook Pharmica, which strengthened Catalent’s biologic manufacturing operations.
Such acquisitions have not only increased Catalent’s market presence but have also diversified its service offerings.
Effect of Strategic Partnerships on Revenue
Catalent’s partnerships with industry giants like Pfizer, Johnson & Johnson, and AstraZeneca have played a pivotal role in boosting its revenue.
These collaborations have allowed the company to expand its role in producing critical vaccines and treatments, especially during the COVID-19 pandemic.
Such partnerships have bolstered Catalent’s revenues, with large-scale manufacturing contracts contributing to the bottom line.
Expansion into New Markets and Product Lines
Catalent’s expansion into vitamins, supplements, and gene therapy has opened up new revenue channels.
The acquisition of Bettera Holdings for $1 billion enabled Catalent to enter the nutritional supplement market, manufacturing vitamins and minerals in gummy form.
This diversification supports the company’s strategy to mitigate risks and enhance growth prospects by entering new consumer health sectors.
Investments in Manufacturing Capacity
The company has consistently invested in expanding its manufacturing capabilities.
Capital investments such as the $12 million expansion of the Kansas City facility and the opening of a new clinical supply facility in Shiga, Japan, have increased production capacity, allowing Catalent to meet growing demand.
This proactive approach in enhancing infrastructure ensures that Catalent remains ahead in terms of production efficiency and capabilities, further driving revenue growth.
Cost Structure and Its Impact on Profitability
While revenue figures have shown promise, Catalent’s profitability has been affected by increased costs.
A significant part of its expenses in FY 2024 stemmed from goodwill impairment charges, totaling $687 million.
Additionally, restructuring costs and expanded operational costs have put pressure on net income, leading to a reported net loss of $1.04 billion.
Despite these challenges, Catalent’s strategic cost management and investments in expansion are expected to positively impact profitability in the coming years.
Revenue Trends Over Recent Fiscal Years
Catalent has experienced varying revenue trends over the past years, with FY 2024 reflecting mixed results. The total revenue of $4.38 billion represents a growth of 3% compared to FY 2023.
Factors like acquisitions, partnerships, and increased manufacturing capacity have positively influenced revenue.
However, declining COVID-related revenues were a dampener, but the company successfully transitioned to focus more on non-COVID services, achieving a nearly 30% growth in non-COVID revenue.
Challenges in Financial Performance
Catalent faced several challenges in FY 2024, such as impairment charges and declining demand for COVID-19 treatments, leading to a net loss of $1.04 billion.
Despite these setbacks, Catalent’s Adjusted EBITDA grew to $703 million, signaling underlying strength in the core business.
These challenges, while impactful, have been counterbalanced by strong business growth in other segments, positioning the company well for future profitability.
FAQs About Catalent
What are Catalent’s Main Business Segments?
Catalent operates primarily in Biologics and Pharma & Consumer Health segments, providing pharmaceutical manufacturing and drug development services.
Who Is the CEO of Catalent?
The current CEO of Catalent is Alessandro Maselli, who has been instrumental in driving the company’s strategic initiatives and growth.
Where Is Catalent’s Headquarters Located?
Catalent’s headquarters are in Somerset, New Jersey, U.S., reflecting its global reach and position as a significant player in the pharmaceutical industry.
How Many Employees Does Catalent Have?
Catalent employs approximately 16,900 people, including scientists, technicians, and support staff, who contribute to the company’s extensive operations globally.
What Was Catalent’s Revenue in 2024?
In FY 2024, Catalent reported a total revenue of $4.38 billion, driven by its various segments, acquisitions, and expanding product lines.
Conclusion
Catalent’s financial journey in 2024 highlights a mix of growth opportunities and challenges.
If you have thoughts on this analysis or want to explore more financial content, feel free to leave comments or visit Ando Money.
